Rewriting Autoimmunity. One Serendipitous Discovery at a Time.

Pioneering a New Era in Autoimmune Therapeutics - Intervening Earlier and More Precisely in Immune Activation

Pioneering Precision Autoimmune Therapies

Serendo Therapeutics, is revolutionizing autoimmune therapeutics by targeting Endophilin A2 (EA2) with precision therapies. Founded by leading scientists and industry experts, we intervene early in the immune cascade to treat autoimmune diseases effectively. Our breakthrough research identifies EA2 as a key regulator in immune activation, enabling us to develop next-generation therapies that suppress disease while maintaining overall immune function. Serendo is advancing a portfolio of innovative small molecule inhibitors for autoimmune indications.

EA2 therapies for effective immune modulation

Endophilin A2 (EA2), encoded by the SH3GL1 gene, is a membrane-sculpting protein previously studied in neuroscience and cancer. At Serendo Therapeutics, we uncovered its unexpected and essential role in immune regulation — specifically in T cell activation.

In autoimmune disease, the immune system misfires, activating T and B cells that attack healthy tissue. EA2 is now known to regulate the internalization and signaling strength of the B- cell and T cell receptors — a critical control point in determining whether these cells becomes activated or remains tolerant.

Our research, published in Nature Communications, shows that inhibiting EA2 disrupts this signaling cascade, selectively dampening the activation of autoreactive T cells. Rodents lacking EA2 are fully protected from developing autoimmune diseases— without compromising their ability to fight infections or cancer.

Norin, U., Rintisch, C., Meng, L. et al. Endophilin A2 deficiency protects rodents from autoimmune arthritis by modulating T cell activation. Nat Commun 12, 610 (2021). https://doi.org/10.1038/s41467-020-20586-2

About Us

Serendo Therapeutics is a science-driven biotechnology company pioneering precision immunotherapies for autoimmune diseases. Our foundation lies in a moment of true serendipity — the unexpected discovery of Endophilin A2 (EA2) as a key regulator of adaptive immunity and immune tolerance.

What began as a genetic anomaly in a rodent model became a paradigm-shifting insight: by modulating EA2, we can prevent harmful autoimmune responses without suppressing the immune system entirely.

At Serendo, we translate this discovery into action. Our team of immunologists, translational scientists, medicinal chemists, and biotech entrepreneurs is building a pipeline of first-in-class therapies targeting EA2.

We are named Serendo because discovery is only the beginning. What matters most is what we do with it.
Bank Cards A line styled icon from Orion Icon Library.

Innovative Science

Harnessing cutting-edge research to pioneer new treatment pathways.
Like Hand A line styled icon from Orion Icon Library.

Precision Therapies

Targeting Endophilin A2 for effective immune modulation.
Wall Clock A line styled icon from Orion Icon Library.

Expert Team

Led by a seasoned leader and supported by world-class advisors in immunology, medicinal chemistry, and biotech innovation

Contact Us

Reach out for inquiries or collaboration opportunities.

ulrika.norin@serendotx.com

Join Us in Redefining Autoimmune Therapeutics

Subscribe to our LinkedIn page to receive updates on our precision therapies targeting Endophilin A2 (EA2) and be the first to know about our groundbreaking advancements in autoimmune treatment.